Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases
International Journal of Radiation Oncology*Biology*Physics · 2024-04 · 118 (5) · 1507-1518
DOI: 10.1016/j.ijrobp.2023.12.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-04. Verfasst von Eugene J Vaios und 16 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Melanoma, Radiosurgery, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI.
Abstract (Originalsprache)
PURPOSE: The intracranial benefit of offering dual immune-checkpoint inhibition (D-ICPI) with ipilimumab and nivolumab to patients with melanoma or non-small cell lung cancer (NSCLC) receiving stereotactic radiosurgery (SRS) for brain metastases (BMs) is unknown. We hypothesized that D-ICPI improves local control compared with SRS alone. METHODS AND MATERIALS: Patients with melanoma or NSCLC treated with SRS from 2014 to 2022 were evaluated. Patients were stratified by treatment with D-ICPI, single ICPI (S-ICPI), or SRS alone. Local recurrence, intracranial progression (IP), and overall survival were estimated using competing risk and Kaplan-Meier analyses. IP included both local and distant intracranial recurrence. RESULTS: Two hundred eighty-eight patients (44% melanoma, 56% NSCLC) with 1,704 BMs were included. Fifty-three percent of patients had symptomatic BMs. The median follow-up was 58.8 months. Twelve-month local control rates with D-ICPI, S-ICPI, and SRS alone were 94.73% (95% CI, 91.11%-96.90%), 91.74% (95% CI, 89.30%-93.64%), and 88.26% (95% CI, 84.07%-91.41%). On Kaplan-Meier analysis, only D-ICPI was significantly associated with reduced local recurrence (P = .0032). On multivariate Cox regression, D-ICPI (hazard ratio [HR], 0.4003; 95% CI, 0.1781-0.8728; P = .0239) and planning target volume (HR, 1.022; 95% CI, 1.004-1.035; P = .0059) correlated with local control. One hundred seventy-three (60%) patients developed IP. The 12-month cumulative incidence of IP was 41.27% (95% CI, 30.27%-51.92%), 51.86% (95% CI, 42.78%-60.19%), and 57.15% (95% CI, 44.98%-67.59%) after D-ICPI, S-ICPI, and SRS alone. On competing risk analysis, only D-ICPI was significantly associated with reduced IP (P = .0408). On multivariate Cox regression, D-ICPI (HR, 0.595; 95% CI, 0.373-0.951; P = .0300) and presentation with >10 BMs (HR, 2.492; 95% CI, 1.668-3.725; P < .0001) remained significantly correlated with IP. The median overall survival after D-ICPI, S-ICPI, and SRS alone was 26.1 (95% CI, 15.5-40.7), 21.5 (16.5-29.6), and 17.5 (11.3-23.8) months. S-ICPI, fractionation, and histology were not associated with clinical outcomes. There was no difference in hospitalizations or neurologic adverse events between cohorts. CONCLUSIONS: The addition of D-ICPI for patients with melanoma and NSCLC undergoing SRS is associated with improved local and intracranial control. This appears to be an effective strategy, including for patients with symptomatic or multiple BMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
- Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
- Duke Cancer Institute Biostatistics, Duke University Medical Center, Durham, North Carolina.
- Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
- Departments of Medical Physics, Duke University Medical Center, Durham, North Carolina.
Förderung
- NCI NIH HHS
- NCI
Zitieren
APA
Vaios, E. J., Shenker, R. F., Hendrickson, P. G., Wan, Z., Niedzwiecki, D., Winter, S. F., Shih, H. A., Dietrich, J., Wang, C., Salama, A. K. S., Clarke, J. M., Allen, K., Sperduto, P., Mullikin, T., Kirkpatrick, J. P., Floyd, S. R., & Reitman, Z. J. (2024). Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases. International Journal of Radiation Oncology*Biology*Physics, 118(5), 1507-1518. https://doi.org/10.1016/j.ijrobp.2023.12.002
Vancouver
Vaios EJ, Shenker RF, Hendrickson PG, Wan Z, Niedzwiecki D, Winter SF, et al. Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases. International Journal of Radiation Oncology*Biology*Physics. 2024;118(5):1507-1518. doi:10.1016/j.ijrobp.2023.12.002
BibTeX
@article{Vaios2024,
author = {Vaios, Eugene J and Shenker, Rachel F and Hendrickson, Peter G and Wan, Zihan and Niedzwiecki, Donna and Winter, Sebastian F and Shih, Helen A and Dietrich, Jorg and Wang, Chunhao and Salama, April K S and Clarke, Jeffrey M and Allen, Karen and Sperduto, Paul and Mullikin, Trey and Kirkpatrick, John P and Floyd, Scott R and Reitman, Zachary J},
title = {Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
volume = {118},
number = {5},
pages = {1507--1518},
doi = {10.1016/j.ijrobp.2023.12.002}
}
EUVIMED